A phase II study of irinotecan in patients with advanced renal cell carcinoma (Q40555866)

21 September 2017

title

A phase II study of irinotecan in patients with advanced renal cell carcinoma (English)

1 reference

21 September 2017

1 reference

Bernard Escudier

1 reference

21 September 2017

Karim Fizazi

1 reference

21 September 2017

Frédéric Rolland

1 reference

21 September 2017

Christine Chevreau

1 reference

21 September 2017

Jean-Pierre Droz

1 reference

21 September 2017

Dominique Mery-Mignard

1 reference

21 September 2017

Stéphane Culine

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

21 September 2017

1 reference

inferred from page(s)

published in

Cancer

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

page(s)

61-65

1 reference

Cancer incidence and mortality in France in 1975-95.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Intrinsic drug resistance in primary and metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Phase II trial of topotecan in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Combination Interleukin-2 and Doxorubicin in Advanced Adult Solid Tumors: Circumvention of Doxorubicin Resistance in Soft-Tissue Sarcoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11474

7 January 2021

Identifiers

DOI

10.1002/CNCR.11474

1 reference

21 September 2017

1 reference